These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22291936)

  • 1. Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.
    Wei H; Hu C; Wang M; van den Hoek AM; Reijmers TH; Wopereis S; Bouwman J; Ramaker R; Korthout HA; Vennik M; Hankemeier T; Havekes LM; Witkamp RF; Verheij ER; Xu G; van der Greef J
    PLoS One; 2012; 7(1):e30332. PubMed ID: 22291936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice.
    Hu C; Wei H; van den Hoek AM; Wang M; van der Heijden R; Spijksma G; Reijmers TH; Bouwman J; Wopereis S; Havekes LM; Verheij E; Hankemeier T; Xu G; van der Greef J
    PLoS One; 2011; 6(5):e19423. PubMed ID: 21611179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
    van den Hoek AM; van der Hoorn JW; Maas AC; van den Hoogen RM; van Nieuwkoop A; Droog S; Offerman EH; Pieterman EJ; Havekes LM; Princen HM
    Diabetes Obes Metab; 2014 Jun; 16(6):537-44. PubMed ID: 24373179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
    de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
    Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systems Analysis of Phenotype Heterogeneity in APOE*3Leiden.CETP Mice Induced by Long-Term High-Fat High-Cholesterol Diet Feeding.
    Paalvast Y; Zhou E; Rozendaal YJW; Wang Y; Gerding A; van Dijk TH; de Boer JF; Rensen PCN; van Dijk KW; Kuivenhoven JA; Bakker BM; van Riel NAW; Groen AK
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
    Gierman LM; Kühnast S; Koudijs A; Pieterman EJ; Kloppenburg M; van Osch GJ; Stojanovic-Susulic V; Huizinga TW; Princen HM; Zuurmond AM
    Ann Rheum Dis; 2014 May; 73(5):921-7. PubMed ID: 23625977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
    van der Hoorn JW; Jukema JW; Havekes LM; Lundholm E; Camejo G; Rensen PC; Princen HM
    Br J Pharmacol; 2009 Apr; 156(7):1067-75. PubMed ID: 19220285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin Reduces Atherosclerosis Development in APOE*3Leiden.CETP Mice Mainly by Reducing NonHDL-Cholesterol.
    Kühnast S; Louwe MC; Heemskerk MM; Pieterman EJ; van Klinken JB; van den Berg SA; Smit JW; Havekes LM; Rensen PC; van der Hoorn JW; Princen HM; Jukema JW
    PLoS One; 2013; 8(6):e66467. PubMed ID: 23840481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.
    Bijland S; van den Berg SA; Voshol PJ; van den Hoek AM; Princen HM; Havekes LM; Rensen PC; Willems van Dijk K
    J Lipid Res; 2010 Jan; 51(1):97-102. PubMed ID: 19564641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein.
    de Vries-van der Weij J; de Haan W; Hu L; Kuif M; Oei HL; van der Hoorn JW; Havekes LM; Princen HM; Romijn JA; Smit JW; Rensen PC
    Endocrinology; 2009 May; 150(5):2368-75. PubMed ID: 19147676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice.
    Li Z; Wang Y; van der Sluis RJ; van der Hoorn JW; Princen HM; Van Eck M; Van Berkel TJ; Rensen PC; Hoekstra M
    Biochem Pharmacol; 2012 Sep; 84(6):821-9. PubMed ID: 22750059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary choline increases brown adipose tissue activation markers and improves cholesterol metabolism in female APOE*3-Leiden.CETP mice.
    Liu C; Song Z; Li Z; Boon MR; Schönke M; Rensen PCN; Wang Y
    Int J Obes (Lond); 2023 Mar; 47(3):236-243. PubMed ID: 36732416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice.
    Jongejan YK; Eikenboom JCJ; Gijbels MJJ; Berbée JFP; van Vlijmen BJM
    J Thromb Thrombolysis; 2021 Oct; 52(3):715-719. PubMed ID: 34052976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.
    de Haan W; de Vries-van der Weij J; Mol IM; Hoekstra M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Biochim Biophys Acta; 2009 Mar; 1791(3):191-7. PubMed ID: 19150509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypical heterogeneity in responder and nonresponder male ApoE*3Leiden.CETP mice.
    Tarasco E; Pellegrini G; Whiting L; Lutz TA
    Am J Physiol Gastrointest Liver Physiol; 2018 Oct; 315(4):G602-G617. PubMed ID: 29975550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of hepatic cholesterol metabolism in CETP/LDLr mice by cholesterol feeding and by drugs (cholestyramine and lovastatin) that lower plasma cholesterol.
    Harada LM; Carrilho AJ; Oliveira HC; Nakandakare ER; Quintão EC
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1209-15. PubMed ID: 17184503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.